Juan Jose Perez Ruixo
Juan Jose Perez Ruixo
Janssen Research & Development
Bestätigte E-Mail-Adresse bei its.jnj.com
Titel
Zitiert von
Zitiert von
Jahr
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem, H Van De Velde, P Karasek, H Oettle, WL Vervenne, ...
Journal of clinical oncology 22 (8), 1430-1438, 2004
8532004
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao, D Cunningham, A De Gramont, W Scheithauer, M Smakal, ...
Journal of Clinical Oncology 22 (19), 3950-3957, 2004
2332004
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer
SRD Johnston, T Hickish, P Ellis, S Houston, L Kelland, M Dowsett, ...
Journal of clinical oncology 21 (13), 2492-2499, 2003
1972003
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
SJ Cohen, L Ho, S Ranganathan, JL Abbruzzese, RK Alpaugh, M Beard, ...
Journal of Clinical Oncology 21 (7), 1301-1306, 2003
1842003
Multi-dimensional function approximation and regression estimation
F Pérez-Cruz, G Camps-Valls, E Soria-Olivas, JJ Pérez-Ruixo, ...
International Conference on Artificial Neural Networks, 757-762, 2002
1152002
Model evaluation of continuous data pharmacometric models: metrics and graphics
THT Nguyen, MS Mouksassi, N Holford, N Al‐Huniti, I Freedman, ...
CPT: pharmacometrics & systems pharmacology 6 (2), 87-109, 2017
1022017
Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys
JJ Xiao, W Krzyzanski, YM Wang, H Li, MJ Rose, M Ma, Y Wu, B Hinkle, ...
The AAPS journal 12 (4), 646-657, 2010
742010
Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis
L Sutjandra, RD Rodriguez, S Doshi, M Ma, MC Peterson, GR Jang, ...
Clinical pharmacokinetics 50 (12), 793-807, 2011
682011
Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients
M Zhu, S Doshi, PO Gisleskog, KS Oliner, JJ Perez Ruixo, E Loh, Y Zhang
Journal of pharmaceutical sciences 103 (1), 328-336, 2014
642014
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
SRD Johnston, VF Semiglazov, GM Manikhas, D Spaeth, G Romieu, ...
Breast cancer research and treatment 110 (2), 327-335, 2008
632008
Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects
YMC Wang, W Krzyzanski, S Doshi, JJ Xiao, JJ Pérez-Ruixo, AT Chow
The AAPS journal 12 (4), 729-740, 2010
592010
Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects
P Olsson-Gisleskog, P Jacqmin, JJ Perez-Ruixo
Clinical pharmacokinetics 46 (2), 159-173, 2007
582007
Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab
BB Yang, P Lum, A Chen, R Arends, L Roskos, B Smith, JJP Ruixo
Clinical pharmacokinetics 49 (11), 729-740, 2010
572010
Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours
L Gibiansky, L Sutjandra, S Doshi, J Zheng, W Sohn, MC Peterson, ...
Clinical pharmacokinetics 51 (4), 247-260, 2012
562012
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma
JE Rosenberg, H von der Maase, JD Seigne, J Mardiak, DJ Vaughn, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
562005
Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin
K Jolling, JJP Ruixo, A Hemeryck, A Vermeulen, T Greway
European journal of pharmaceutical sciences 24 (5), 465-475, 2005
522005
Prediction of cyclosporine dosage in patients after kidney transplantation using neural networks
G Camps-Valls, B Porta-Oltra, E Soria-Olivas, JD Martín-Guerrero, ...
IEEE Transactions on Biomedical Engineering 50 (4), 442-448, 2003
482003
Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis®) in cancer patients
JJ Perez-Ruixo, P Zannikos, S Hirankam, K Stuyckens, EA Ludwig, ...
Clinical pharmacokinetics 46 (10), 867-884, 2007
472007
Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma
XS Xu, X Yan, T Puchalski, S Lonial, HM Lokhorst, PM Voorhees, ...
Clinical Pharmacology & Therapeutics 101 (6), 721-724, 2017
43*2017
Mechanism‐based pharmacokinetic/pharmacodynamic meta‐analysis of trabectedin (ET‐743, Yondelis) induced neutropenia
J Hing, JJ Perez‐Ruixo, K Stuyckens, A Soto‐Matos, L Lopez‐Lazaro, ...
Clinical Pharmacology & Therapeutics 83 (1), 130-143, 2008
432008
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20